NCT06659770View on ClinicalTrials.gov

A Real-World Observational Study: Zevorcabtagene Autoleucel Injection in Patients with Relapsed/Refractory Multiple Myeloma

Not yet recruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
DRUG

Zevorcabtagene Autoleucel

Zevorcabtagene Autoleucel is a novel fully human BCMA-targeting CAR-T therapy

Sponsors
All Listed Sponsors
lead

CARsgen Therapeutics Co., Ltd.

INDUSTRY